山东大学耳鼻喉眼学报 ›› 2026, Vol. 40 ›› Issue (2): 125-132.doi: 10.6040/j.issn.1673-3770.0.2024.125

• 综述 • 上一篇    

睑板腺功能障碍相关干眼的局部药物治疗

宁煜赟1,李彤2,张馨心3   

  1. 1.山西医科大学 研究生院, 山西 太原 030000;
    2.山西医科大学第二医院 眼科, 山西 太原 030000;
    3.山西省眼科医院 综检科, 山西 太原 030000
  • 发布日期:2026-03-26
  • 通讯作者: 李彤. E-mail:lt8101007@163.com
  • 基金资助:
    山西省青年科学研发项目(202203021212072)

Topical pharmacologic treatment of dry eye disease associated with meibomian gland dysfunction

NING Yuyun1, LI Tong2, ZHANG Xinxin3   

  1. 1. Graduate School, Shanxi Medical University, Taiyuan 030000, Shanxi, China2. Department of Ophthalmology, The Second Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi, China3. Comprehensive Examination Department, Shanxi Provincial Eye Hospital, Taiyuan 030000, Shanxi, China
  • Published:2026-03-26

PDF (PC)

12

摘要： 干眼是影响全球数百万人的常见多因素眼表疾病,随着社会的快速发展其发病率不断上升。睑板腺功能障碍引发的泪膜结构、性状和眼表稳态改变,是导致干眼的主要因素之一,治疗方式包括药物、物理及手术干预。其中局部药物治疗可选择抗菌药、含脂人工泪液、抗炎药、促泪液分泌剂、激素眼用制剂及全氟己基辛烷等新型药物。本文就睑板腺功能障碍相关干眼的局部药物治疗进行综述。

关键词: 睑板腺功能障碍, 干眼, 泪膜脂质层, 全氟己基辛烷

Abstract: Dry eye is a common multifactorial ocular surface disease that affects millions of people worldwide, and its incidence is increasing with the rapid development of society. Alterations in tear film structure, properties, and ocular surface homeostasis triggered by meibomian gland dysfunction are one of the major factors contributing to dry eye. Treatment modalities include pharmacologic, physical, and surgical interventions. Topical pharmacotherapy options include antimicrobials, lipid-containing artificial tears, anti-inflammatory agents, tear secretion promoters, hormonal ophthalmic preparations, and novel drugs such as perfluorohexyloctane. This article reviews the topical pharmacologic treatment of dry eye associated with meibomian gland dysfunction.

Key words: Meibomian gland dysfunction, Dry eye disease, Tear film lipid layer, Perfluorohexane

中图分类号: 

  • R777.34
[1] Liu S, Yang G, Li QN, et al. Safety and efficacy of topical diquafosol for the treatment of dry eye disease: an updated meta-analysis of randomized controlled trials[J]. Indian Journal of Ophthalmology, 2023, 71(4): 1304-1315. doi:10.4103/IJO.IJO_268_23
[2] 亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组. 中国干眼专家共识: 治疗(2020年)[J]. 中华眼科杂志, 2020, 56(12): 907-913. doi:10.3760/cma.j.cn112142-20200925-00618
[3] Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape[J]. Ophthalmology and Therapy, 2023, 12(3): 1397-1418. doi:10.1007/s40123-023-00669-1
[4] Rolando M, Zierhut M, Barabino S. Should we reconsider the classification of patients with dry eye disease [J]. Ocular Immunology and Inflammation, 2021, 29(3): 521-523. doi:10.1080/09273948.2019.1682618
[5] Rolando M, Merayo-lloves J. Management strategies for evaporative dry eye disease and future perspective[J]. Current Eye Research, 2022, 47(6): 813-823. doi:10.1080/02713683.2022.2039205
[6] Lam SM, Tong L, Duan XR, et al. Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles[J]. Journal of Lipid Research, 2014, 55(2): 289-298. doi:10.1194/jlr.M044826
[7] Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease[J]. Pharmaceutics, 2021, 13(2): 207. doi:10.3390/pharmaceutics13020207
[8] Khanal S, Bai YQ, Nao W, et al. Human meibum and tear film derived cholesteryl and wax esters in meibomian gland dysfunction and tear film structure[J]. The Ocular Surface, 2022, 23: 12-23. doi:10.1016/j.jtos.2021.10.009
[9] 蒋冬冬, 靳荷. 睑板腺功能障碍相关干眼的诊疗进展[J]. 国际眼科杂志, 2021, 21(7): 1209-1212. doi:10.3980/j.issn.1672-5123.2021.7.16
[10] Gurlevik U, Karakoyua A, Yasar E. Does Sjogren's syndrome affect only the lacrimal gland in the eye Time to replace the missing stones[J]. Indian Journal of Ophthalmology, 2021, 69(1): 53-57. doi:10.4103/ijo.IJO_2383_19
[11] Chhadva P, Goldhardt R, Galor A. Meibomian gland disease the role of gland dysfunction in dry eye disease[J]. Ophthalmology, 2017, 124(11): S20-S26. doi:10.1016/j.ophtha.2017.05.031
[12] 李威, 张斌. 优化脉冲光联合睑板腺按摩治疗睑板腺功能障碍的临床效果观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 105-109. doi:10.6040/j.issn.1673-3770.0.2020.341
[13] 亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组.中国睑板腺功能障碍专家共识:定义和分类(2023年)[J]. 中华眼科杂志, 2023, 59(4): 256-261. doi:10.3760/cma.j.cn112142-20230114-00023.
[14] 狄宇. 干眼炎症反应机制及抗炎治疗的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 144-150. doi:10.6040/j.issn.1673-3770.0.2020.484
[15] Holland EJ, Jackson MA, Donnenfeld E, et al. Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials[J]. JAMA Ophthalmology, 2021, 139(11): 1200-1208. doi:10.1001/jamaophthalmol.2021.3943
[16] Malmin A, Thomseth VM, Frland PT, et al. Associations between serial intravitreal injections and dry eye[J]. Ophthalmology, 2023, 130(5): 509-515. doi:10.1016/j.ophtha.2023.01.009
[17] Capasso L, Abbinante G, Coppola A, et al. Recent evidence of tea tree oil effectiveness in blepharitis treatment[J]. BioMed Research International, 2022, 2022(1): 9204251. doi:10.1155/2022/9204251
[18] Jacobi C, Doan S, Pavel V, et al. Different approach to Manage Demodex Blepharitis-initial and maintenance treatment[J]. Current Eye Research, 2022, 47(3): 352-360. doi:10.1080/02713683.2021.1978099
[19] Liu WT, Gong L. Anti-demodectic effects of okra eyelid patch in Demodex blepharitis compared with tea tree oil[J]. Experimental and Therapeutic Medicine, 2021, 21(4): 338. doi:10.3892/etm.2021.9769
[20] Navel V, Mullez A, Benoist d'Azy C, et al. Efficacy of treatments for demodex blepharitis: a systematic review and meta-analysis[J]. The Ocular Surface, 2019, 17(4): 655-669. doi:10.1016/j.jtos.2019.06.004
[21] Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review[J]. Survey of Ophthalmology, 2020, 65(2): 205-217. doi:10.1016/j.survophthal.2019.08.007
[22] Stroman DW, Mintun K, Epstein AB, et al. Reduction in bacterial load using hypochlorous acid hygiene solution on ocular skin[J]. Clin Ophthalmol, 2017, 11: 707-714. doi:10.2147/opth.s132851
[23] Correia S, Poeta P, Hébraud M, et al. Mechanisms of quinolone action and resistance: where do we stand [J]. Journal of Medical Microbiology, 2017, 66(5): 551-559. doi:10.1099/jmm.0.000475
[24] 许海嘉, 李蓓, 范罕英, 等. 药物联合物理疗法治疗MGD所致干眼的疗效观察[J]. 国际眼科杂志, 2019, 19(10): 1787-1790. doi:10.3980/j.issn.1672-5123.2019.10.36
[25] 孙圣书, 黄悦. 抗生素治疗睑板腺功能障碍的研究进展[J]. 国际眼科杂志, 2022, 22(5): 827-832. doi:10.3980/j.issn.1672-5123.2022.5.26
[26] Mah FS, Karpecki PM. Review of loteprednol etabonate 0.5%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis[J]. Ophthalmology and Therapy, 2021, 10(4): 859-875. doi:10.1007/s40123-021-00401-x
[27] 胡晓娟, 卢丽丽, 刘猛. 睑板腺按摩联合抗生素滴眼液治疗睑板腺功能障碍性干眼的效果[J]. 医学信息, 2020, 33(14): 76-79. doi:10.3969/j.issn.1006-1959.2020.14.022
[28] Jerkins G, Greiner JV, Tong L, et al. A comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease[J]. Clinical Ophthalmology, 2020, 14: 1665-1673. doi:10.2147/OPTH.S256351
[29] Chan TCY, Chow SSW, Wan KHN, et al. Update on the association between dry eye disease and meibomian gland dysfunction[J]. Medical Journal, 2019, 25(1): 38-47. doi:10.12809/hkmj187331
[30] Labetoulle M, Benitez-del-castillo JM, BARABINO S, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease[J]. International Journal of Molecular Sciences, 2022, 23(5): 2434. doi:10.3390/ijms23052434
[31] 陆菁, 刘辰, 吴晋晖, 等. 人工泪液成分的最新研究及进展[J]. 中南药学, 2022, 20(11): 2635-2641. doi:10.7539/j.issn.1672-2981.2022.11.031
[32] Li Y, Cui L, Lee HS, et al. Comparison of 0.3% hypotonic and isotonic sodium hyaluronate eye drops in the treatment of experimental dry eye[J]. Current Eye Research, 2017, 42(8): 1108-1114. doi:10.1080/02713683.2017.1297462
[33] Liu Z, Chen D, Chen X, et al. Trehalose induces autophagy against inflammation by activating TFEB signaling pathway in human corneal epithelial cells exposed to hyperosmotic stress[J]. Investigative Ophthalmology & Visual Science, 2020, 61(10): 26. doi:10.1167/iovs.61.10.26
[34] Goldstein MH, Silva FQ, Blender N, et al. Ocular benzalkonium chloride exposure: problems and solutions[J]. Eye(London, England), 2022, 36(2): 361-368. doi:10.1038/s41433-021-01668-x
[35] Kallab M, Szegedi S, Hommer N, et al. Correction to: topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial[J]. Advances in Therapy, 2020, 37(1): 342-343. doi:10.1007/s12325-019-01190-3
[36] Prinz J, Maffulli N, Fuest M, et al. Efficacy of topical administration of corticosteroids for the management of dry eye disease: systematic review and meta-analysis[J]. Life, 2022, 12(11): 1932. doi:10.3390/life12111932
[37] Messmer EM, Ahmad S, Del Castillo JMB, et al. Management of inflammation in dry eye disease: recommendations from a European panel of experts[J]. European Journal of Ophthalmology, 2023, 33(3): 1294-1307. doi:10.1177/11206721221141481
[38] Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease[J]. Expert Opinion on Pharmacotherapy, 2018, 19(9): 1027-1039. doi:10.1080/14656566.2018.1479742
[39] Rhim JW, Eom Y, Yoon EG, et al. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction[J]. Japanese Journal of Ophthalmology, 2022, 66(3): 254-263. doi:10.1007/s10384-022-00906-3
[40] Tauber J. A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction[J]. Cornea, 2020, 39(4): 403-407. doi:10.1097/ICO.0000000000002235
[41] Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study[J]. Cornea, 2016, 35(6): 741-748. doi:10.1097/ICO.0000000000000803
[42] Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre[J]. Indian Journal of Ophthalmology, 2023, 71(4): 1598-1602. doi:10.4103/IJO.IJO_2586_22
[43] Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study[J]. Scientific Reports, 2019, 9(1): 9091. doi:10.1038/s41598-019-45475-7
[44] Katagiri A, Tsubota K, Mikuzuki L, et al. Diquafosol sodium reduces neuronal activity in trigeminal subnucleus caudalis in a rat model of chronic dry eye disease[J]. Neuroscience Letters, 2023, 792: 136939. doi:10.1016/j.neulet.2022.136939
[45] 刘子彬, 张蕊, 李能, 等. 3%地夸磷索钠滴眼液治疗睑板腺功能障碍相关性干眼[J]. 国际眼科杂志, 2022, 22(8): 1271-1276. doi:10.3980/j.issn.1672-5123.2022.8.07
[46] Wang LX, Deng YP. Androgen and meibomian gland dysfunction: from basic molecular biology to clinical applications[J]. International Journal of Ophthalmology, 2021, 14(6): 915-922. doi:10.18240/ijo.2021.06.18
[47] Goleiowski B, Badarudin N, Eden J, et al. The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study[J]. British Journal of Ophthalmology, 2017, 101(7): 926-932. doi:10.1136/bjophthalmol-2016-309498
[48] Ibrahim MAA, Elwan WM. Role of topical dehydroepiandrosterone in ameliorating isotretinoin-induced Meibomian gland dysfunction in adult male albino rat[J]. Annals of Anatomy - Anatomischer Anzeiger, 2017, 211: 78-87. doi:10.1016/j.aanat.2017.01.007
[49] Stolowich N, Vittitow J, Kissling R, et al. Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease[J]. Current Therapeutic Research, 2023, 98: 100705. doi:10.1016/j.curtheres.2023.100705
[50] Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction results of the randomized phase 3 GOBI study[J]. Ophthalmology, 2023, 130(5): 516-524. doi:10.1016/j.ophtha.2022.12.021
[51] Delicado-Miralles M, Velasco E, Díaz-Tahoces A, et al. Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain[J]. Frontiers in Medicine, 2021, 8: 709712. doi:10.3389/fmed.2021.709712
[52] Vittitow J, Kissling R, Decory H, et al. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease[J]. Current Therapeutic Research, 2023, 98: 100704. doi:10.1016/j.curtheres.2023.100704
[53] Tian L, Gao ZJ, Zhu L, et al. Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial[J]. JAMA Ophthalmology, 2023, 141(4): 385-392. doi:10.1001/jamaophthalmol.2023.0270
[1] 方璐, 雷玉丹, 王华. 环孢素滴眼液联合玻璃酸钠滴眼液治疗干眼临床效果的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 65-73.
[2] 李语辰,王旭. 巩膜镜治疗严重眼表疾病的有效性和安全性[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 149-154.
[3] 毕赵静,李元彬. 睑板腺功能障碍实验模型及应用现状[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 159-165.
[4] 叶强,洛松巴宗,南苏亭,王浩,马进海,律鹏,张文芳. 色素上皮衍生因子与干眼的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 151-156.
[5] 王佳慧,刘学勤. 全球近10年干眼相关生活质量研究——基于VOSviewer和CiteSpace的文献计量学及可视化分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 61-72.
[6] 段练,孟凡兰,党光福. 干眼对屈光性白内障手术的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 1-6.
[7] 李彦松综述朱玉广审校. 泪膜稳定性对超声乳化术后视觉质量影响的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 19-25.
[8] 白伶伶,王红星,王立春. 可吸收泪小管塞栓联合人工泪液治疗中重度干眼的有效性及对视觉相关生存质量的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 78-82.
[9] 狄宇，李莹. 干眼炎症反应机制及抗炎治疗的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 144-150.
[10] 黄天泽,陈迪,李莹. 机器学习在眼表疾病诊断及角膜手术中的应用进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 13-19.
[11] 肖西立,聂渝晓,陈婕. 国内近10年干眼相关研究——基于Citespace的可视化分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 86-97.
[12] 李威,张斌. 优化脉冲光联合睑板腺按摩治疗睑板腺功能障碍的临床效果观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 105-109.
[13] 孙子雯,崔洪玮,孙喜灵,陈晨,张璐,胡竹林. 干眼病的病因、发病机制及治疗进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 159-166.
[14] 涂雪峰. 重组牛碱性成纤维细胞生长因子联合玻璃酸钠治疗干眼症的疗效分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 84-87.
[15] 阳雪,李莹. 干眼对角膜内皮细胞的影响及相关因素分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 72-76.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 邓基波,孙奉乾,许安廷 . 大前庭导水管综合征[J]. 山东大学耳鼻喉眼学报, 2006, 20(2): 116 -118 .
[2] 周子宁,金国威 . 喉气管狭窄的预防和治疗进展[J]. 山东大学耳鼻喉眼学报, 2006, 20(5): 462 -465 .
[3] 徐赛男,杨雷 . 红霉素促进鼻息肉上皮细胞凋亡的实验研究[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 27 -29 .
[4] 刘联合 . 颈深部脓肿37例[J]. 山东大学耳鼻喉眼学报, 2008, 22(2): 180 -181 .
[5] 潘小华,边 疆 . 鼻内镜下经口与经鼻行儿童腺样体切除术的比较[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 248 -249 .
[6] 金向阳,林 海 . 侵袭型曲菌性鼻窦炎侵犯右眼眶、双乳突及左肺1例[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 259 -259 .
[7] 孙 岩,张庆泉,张 华,宋西成,赵利敏,王 艳,姜绍红,王 强 . 异种（牛）脱细胞真皮基质修复膜在耳鼻咽喉头颈外科术后缺损修复的应用[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 316 -319 .
[8] 皮士军,曹桂霞,张文山,马 庆,黄 健 . 鼻内镜和纤维喉镜联合应用切除上颌窦黏膜下囊肿[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 347 -348 .
[9] 王建荣,张晨明,刘 伟,栗映梅,位 宁 . 超声生物显微镜（UBM）在闭角型青光眼手术前后的应用[J]. 山东大学耳鼻喉眼学报, 2008, 22(4): 359 -361 .
[10] 袁 英,杨淑娟,王领台,刘付星,孙新中 . 硬腭截短-咽侧成型术治疗悬雍垂腭咽成型术后复发8例[J]. 山东大学耳鼻喉眼学报, 2008, 22(5): 395 -397 .
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发